83% of peptide-aware Americans want the FDA to make peptides more accessible

  Days before an FDA advisory committee meets to consider whether seven widely used peptides — BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon — should become eligible for compounding, a new survey suggests that’s what Americans want. Among 2,491 U.S. adults familiar with peptides as a health and wellness tool surveyed by longevity